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Abstract
Background: Abnormal hemostasis in cancer patients has previously been described, however
the correlation between the plasma fibrinogen level and cancer metastasis and prognosis has not
been reported in a large-scale clinical study.
Methods: Preoperative plasma fibrinogen levels were retrospectively examined in 405 patients
who underwent surgery for advanced gastric cancer. The association of fibrinogen levels with
clinical/pathological findings and clinical outcome was evaluated.
Results: There was a positive correlation between plasma fibrinogen levels and the depth of
invasion (p < 0.05). Hyperfibrinogenemia (>310 mg/dl) was independently associated with lymph
node (Odds Ratio; 2.342, P = 0.0032) and liver (Odds Ratio; 2.933, P = 0.0147) metastasis, not with
peritoneal metastasis in this series. Patients with hyperfibrinogenemia showed worse clinical
outcome in T2 gastric cancer, however, there was no correlation of plasma fibrinogen level with
prognosis in T3/T4 gastric cancer.
Conclusion: Our results might support the idea that hyperfibrinogenemia can augment lymphatic
and hematogeneous metastasis of advanced gastric cancer, which is major determinant of the
prognosis in T2 gastric cancer. Therefore, in the situation without peritoneal involvement,
hyperfibrinogenemia is a useful biomarker to predict the possible metastasis and worse clinical
outcome in T2 gastric cancer.
Background
An increased frequency of thrombosis in patients with
gastrointestinal cancer was first documented in 1865 [1].
Since then, a number of studies have focused on the rela-
tionship between various cancers and hemostatic factors.
Abnormalities in blood coagulation are detectable in
patients with malignancy, including thrombocytosis and
elevated markers of coagulation activation such as frag-
ment 1+2, thrombin-antithrombin III complexes (TAT),
fibrinopeptide A (FPA), and D-Dimer [2-4]. More
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recently, a correlation between these factors and the prog-
nosis of malignancies was documented. Thrombocytosis
is thought to be associated with poor prognosis in gastric
cancer [5], as well as esophageal cancer [6], lung cancer
[7], colon cancer [7], renal cell carcinoma [8], and gyne-
cological malignancies [9], D-Dimer is also reported to be
associated with poor prognosis in patients with lung can-
cer [10,11] and colorectal cancer [12,13] as well as being
a good predictor of survival and disease progression.
Fibrinogen, an essential hemostatic factor, is converted to
fibrin (a final product of the hemostatic pathway) by acti-
vated thrombin. Dvorak suggested that elevated fibrino-
gen concentrations were frequently observed in cancer
patients with malignant disease [14]. Moreover, in gastric
cancer, preoperative plasma fibrinogen levels correlate
with extent of tumor [15]. In our previous study, we found
that preoperative plasma fibrinogen level was a useful pre-
dictor for lymph node metastasis in patients with gastric
cancer [16]. Tumor marker carcinoembryonic antigen
(CEA) as well as inflammatory biomarker C-reactive pro-
tein (CRP) did not show the independent association
with lymph node metastasis, suggesting that hyperfibrin-
ogenemia was not a simple result of cancer progression
and might support the metastatic process by providing
beneficial microenvironment around the tumor. This idea
can be partially supported by recent studies in fibrinogen-
deficient mice that revealed hematogeneous and lym-
phatic metastases were greatly reduced, indicating the
positive roles of fibrinogen in the metastatic progression
of cancer [17-19]. Taken together with our previous
results, we hypothesized that fibrinogen might augment
metastasis in human as well, and a higher level of plasma
fibrinogen might be a good clinical marker of metastatic
disease and worse clinical outcome. Based on this
assumption, we focused on the possible impact of preop-
erative plasma fibrinogen level on gastric cancer progno-
sis. We retrospectively examined the preoperative plasma
fibrinogen level of patients with advanced gastric cancer
who underwent gastrectomy, and evaluated an associa-
tion of these findings with clinical and pathological fac-
tors as well as clinical outcome.
Methods
A total of 442 patients with advanced gastric cancer under-
went gastrectomy between January 1985 and December
1999 at the First Department of Surgery, University of
Tokyo Hospital, Tokyo. Oral consent was obtained from
each patient for blood test. Among them, plasma fibrino-
gen levels were evaluated before surgery in 424 patients.
Because the plasma fibrinogen level is critically affected by
the presence of inflammation, liver cirrhosis and chronic
renal failure, five patients with apparent acute inflamma-
tory disease (two with acute cholecystitis, three with acute
peritonitis due to stomach perforation), 10 patients with
liver cirrhosis and four patients with chronic renal failure
were excluded from the study to minimize confounding
factors. The remaining 405 patients were enrolled in this
study. We also evaluated fibrinogen levels in 387 patients
with early gastric cancer and 124 patients with non-
inflammatory benign disease who underwent surgery dur-
ing the same period. Our protocol was approved by the
ethics committee of faculty of medicine, the University of
Tokyo.
In this study we referred to the classifications established
by the Japanese Research Society for Gastric Cancer [20]
which define T1 as a lesion confined to the mucosal or
submucosal layer; T2 as a tumor invading the proper mus-
cle layer or subserosa; T3 as a tumor penetrating serosal
without invasion of adjacent structures; and T4 as a tumor
invading adjacent structures. Histological classifications
were defined as follows: differentiated carcinoma – well
and moderately differentiated tubular adenocarcinoma
and papillary adenocarcinoma; undifferentiated carci-
noma – poorly differentiated adenocarcinoma, signet ring
cell carcinoma and mucinous carcinoma.
The preoperative plasma fibrinogen level was measured
from early morning samples taken before breakfast five to
ten days before surgery. It had been determined by Clauss
clotting method using DADE Thrombin Reagent™ and
Coagrex-700™ automated coagulometer (both from Sys-
mex, Kobe, Japan). The reference range of plasma fibrino-
gen level was defined as between 210 and 310 mg/dl
according to the mean value ± 2 SD of healthy volunteers;
plasma fibrinogen levels above 310 mg/dl were defined as
hyperfibrinogenemia tentatively in this study.
Statistical analysis was carried out using JMP 5.1 (SAS
Institute, Cary, NC). Plasma fibrinogen levels were com-
pared with one-way ANOVA followed by the SNK test.
The association of fibrinogen levels with clinicopatholog-
ical factors was assessed with Fisher's exact test. A multi-
variate stepwise logistic regression analysis was performed
to identify independent variables that were correlated
with hematogenous and lymphatic metastasis. The Kap-
lan-Meier method was used to estimate the distribution of
survival curve, and log-rank test was used to compare the
distributions between the groups with or without hyperfi-
brinogenemia. P < 0.05 was considered significant for all
statistical analyses.
Results
The association of plasma fibrinogen level with the depth 
of invasion and metastatic disease in gastric cancer
The mean ± standard deviation (SD) plasma fibrinogen
level in the 792 patients studied was 289.5 ± 81.3 mg/dl,
which was not statistically different from patients with
benign disease (278.1 ± 43.5) (Figure 1). However, whenBMC Cancer 2006, 6:147 http://www.biomedcentral.com/1471-2407/6/147
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patients were classified into 3 groups according to the T
classification of gastric cancer, patients with T2 and T3/T4
cancer showed significantly higher fibrinogen levels than
those with benign disease or those with T1 cancer (T2
304.3 ± 85.0, p < 0.01; T3/T4 327.8 ± 101.2, p < 0.01).
Interestingly, an increase in the plasma fibrinogen level
correlated with an increase in the depth of invasion,
showing a statistically significant difference among
patients when evaluated by ANOVA (p < 0.0001). The
fibrinogen levels in patients with localized disease, lymph
node metastases, liver metastasis and peritoneal metasta-
sis were summarized in Table 1. In patients with localized
disease, preoperative fibrinogen level (mean value; 266.6)
was significantly lower than that in patients with lymph
Plasma fibrinogen level of 124 patients with benign disease and 792 patients with gastric cancer Figure 1
Plasma fibrinogen level of 124 patients with benign disease and 792 patients with gastric cancer. Note that there is no differ-
ence in fibrinogen levels between benign and cancer patients, although it gradually increases with increasing depth of cancer 
invasion (one way ANOVA with SNK test; p < 0.0001). Values are the mean (standard deviation) levels for individual patients. 
*The mean values of plasma fibrinogen were significantly different between the groups of T1 and T2 (P < 0.01), between the 
groups of T1 and T3/T4 (P < 0.01), and between the groups of T2 and T3/T4 (p < 0.01).
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Table 1: Preoperative plasma fibrinogen level of the patients with or without metastases.
number plasma fibrinogen level (mg/dl) s.d.
localized disease 456 266.6 62.8
lymph node metastasis 336 320.5 92.7
liver metastasis 28 356.6 94.0
peritoneal metastasis 41 345.0 92.9
s.d; standard deviationBMC Cancer 2006, 6:147 http://www.biomedcentral.com/1471-2407/6/147
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node metastasis (320.5; P < 0.0001), liver metastasis
(356.6; P < 0.0001), peritoneal metastasis (345.0; P <
0.0001).
The association of hyperfibrinogenemia with lymph node, 
liver, and peritoneal metastasis in advanced gastric cancer
Of 405 patients with advanced cancer, lymph node metas-
tases in 301 patients, liver metastases in 28, and perito-
neal metastases in 41 were identified. Univariate analysis
revealed that lymph node metastases were significantly
associated with many pathologic factors such as size of the
tumor, serosal invasion, lymphatic and venous involve-
ment as well as plasma fibrinogen level (Table 2). Multi-
variate analysis indicated that hyperfibrinogenemia
showed an independent association with lymph node
metastases with an odds ratio of 2.342 (p < 0.01) (Table
3). Subsequently, we focused on distant hematogeneous
and peritoneal metastases. In individuals with advanced
gastric cancer, hyperfibrinogenemia showed a positive
association with liver metastasis (p < 0.01), not with peri-
toneal dissemination, by univariate analysis (Table 2).
Multivariate analysis showed that hyperfibrinogenemia,
in addition to differentiated histology and venous
involvement, remained independently associated with
liver metastasis with an odds ratio of 2.933 (p < 0.05)
(Table 3).
Table 2: Relationship between clinicopathological factors and metastasis in advanced gastric cancer
lymph node metastasis liver metastasis peritoneal metastasis
variables total negative positive P value negative positive P value negative positive P value
age (years)
≤59 192 56 136 183 9 170 22
≥60 213 48 165 0.1394 194 19 0.1168 194 19 0.4142
gender
male 284 76 208 264 20 258 26
female 121 28 93 0.5345 113 8 >0.9999 106 15 0.3684
tumor 
location
upper 124 31 93 117 7 107 17
middle 152 40 112 143 9 134 18
lower 129 33 96 0.969 117 12 0.4303 123 6 0.0389
differentiat
ion
differentiat
ed
180 46 134 162 18 165 15
undifferent
iated
225 58 167 >0.9999 215 10 0.0314 199 26 0.3225
lymphatic 
involveme
nt
negative 125 68 57 119 6 119 6
positive 280 36 244 <0.0001 258 22 0.2974 245 35 0.0196
venous 
involveme
nt
negative 195 60 135 190 5 180 15
positive 210 44 166 0.0303 187 23 0.0008 184 26 0.1386
serosal 
invasion
negative 240 91 149 226 14 235 5
positive 165 13 152 <0.0001 151 14 0.3236 129 36 <0.0001
tumor size 
(cm)
≤6 215 80 135 202 13 206 9
>6 190 24 166 <0.0001 175 15 0.5571 158 32 <0.0001
Plasma 
fibrinogen 
(mg/dl)
≤310 234 76 158 226 8 216 18
≥311 171 28 143 0.0002 151 20 0.0014 148 23 0.067BMC Cancer 2006, 6:147 http://www.biomedcentral.com/1471-2407/6/147
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The clinical outcome in T2 and T3/T4 gastric cancer with 
or without hyperfibrinogenemia
In T2 gastric cancer, patients without hyperfibrinogene-
mia showed an extremely good outcome even in the pop-
ulation with advanced cancer, and the survival rate was
significantly lower for patients with hyperfibrinogenemia
(P = 0.001; log-rank test) (Figure 2A). In marked contrast,
hyperfibrinogenemia did not show any correlation with
5-year survival rate in T3/T4 gastric cancer, i.e. cancer
invading beyond the serosal (Figure 2B).
Discussion
A link between hyperfibrinogenemia and cardiovascular
diseases such as coronary heart disease, stroke and periph-
eral vascular disease was previously revealed [21]. Simi-
larly, a recent study by Preston and colleagues indicates
that fibrinogen production is upregulated in patients with
pancreatic adenocarcinoma, although the tumor stage
was not determined [22]. This suggests a positive role for
fibrinogen in the progression of malignant diseases. In the
present study we found that fibrinogen levels in patients
with gastric cancer did not show statistically significant
difference from those in individuals with benign diseases.
However, the plasma fibrinogen level gradually increased
with increasing depth of tumor, and the fibrinogen levels
of patients with advanced gastric cancer were significantly
higher than patients with benign diseases or early tumors.
Moreover, the fibrinogen levels were also significantly
higher in patients with metastatic disease, which essen-
tially supports the previous study of another group [15].
Hyperfibrinogenemia is a clinically relevant event in
advanced stage and our results strongly suggest that fibrin-
ogen is involved in the progression of gastric cancer dur-
ing the latter phase of the disease.
Recent studies in fibrinogen deficient mice provide clear
evidence that fibrinogen plays a crucial role in hematoge-
nous and lymphatic metastasis of cancer cells [18]. They
showed that fibrinogen (Aα-chain)-deficient mice with
intravenously transferred Lewis lung carcinoma (LLC) or
B16 melanoma had a significantly reduced incidence of
lung metastasis compared with wild type mice [17]. Also,
the number of metastases in regional lymph nodes and
the lungs of these transgenic mice was markedly reduced
when LLC was subcutaneously inoculated [18]. These
results raised the possibility that hyperfibrinogenemia
might function to enhance metastasis formation as com-
pared to the low fibrinogen level. As a fact, hyperfibrino-
genemia showed an independent association with lymph
node metastasis in human gastric cancer [16]. Interest-
ingly, there was no remarkable difference in the growth of
subcutaneously transplanted tumors between fibrinogen-
deficient and wild type mice [18], indicating that fibrino-
gen plays a major role in the development of metastases
but not in the growth of the primary tumor. This is exactly
consistent with our human study in which patients with
early gastric cancer had a similar plasma fibrinogen level
to benign subjects.
In our study, we found that plasma fibrinogen level was
associated with worse prognosis in T2 gastric cancer as
well as lymphatic and hematogenous metastasis. The
impact of hyperfibrinogenemia, however, was not found
in T3/T4 gastric cancer. T3/T4 gastric cancers are serosal-
infiltrating tumors, which enhances the potential to have
occult metastatic foci on the peritoneum and/or form the
overt peritoneal metastasis. As a fact, peritoneum is the
major site of recurrence in T3/T4 gastric cancers [23-25],
and the prognosis of T3/T4 cancers mainly determined by
this type of recurrence. In contrast, T2 cancer has a less fre-
quency of peritoneal metastasis as compared with T3/T4
cancer and liver or lymph node relapse seems to be major
determinant of clinical outcome in T2 cancer. In our
study, however, we found no association of hyperfibrino-
genemia with peritoneal metastasis, although hyperfi-
brinogenemia was an independently associated factor
Table 3: Relationship between clinicopathological factors and metastasis in advanced gastric cancer (multivariate analysis)
lymph node metastasis
odds ratio 95% CI P value
serosal invasion 3.983 1.991 7.970 <0.0001
tumor size 1.965 1.088 3.546 0.0251
lymphatic involvement 5.780 3.333 10.000 <0.0001
venous involvement 0.746 0.426 1.308 0.3067
hyperfibrinogenemia 2.342 1.330 3.546 0.0032
liver metastasis
odds ratio 95% CI P value
differentiated type 2.439 1.070 5.556 0.0341
venous involvement 4.463 1.631 12.214 0.0036
hyperfibrinogenemia 2.933 1.236 6.944 0.0147BMC Cancer 2006, 6:147 http://www.biomedcentral.com/1471-2407/6/147
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with lymph node and liver metastasis. We speculate that
peritoneal metastasis has a strong impact on the clinical
outcome in T3/T4 gastric cancer and therefore plasma
fibrinogen level was not a prognostic marker in this pop-
ulation. These results suggested that some patients with
hyperfibrinogenemia could not be cured by surgical
modalities in T2 gastric cancer and chemotherapy might
be required for the improvement of survival in this popu-
lation. The clinical benefit of neoadjuvant and/or adju-
vant chemotherapy has not been clearly determined in T2
gastric cancer. From our data, we can conclude that
patients with hyperfibrinogenemia might be good candi-
dates for neoadjuvant and/or adjuvant chemotherapy in
T2 gastric cancer. Patients with T3/T4 gastric cancer will be
candidates regardless of the plasma fibrinogen level.
Fibrinogen may enhance metastasis through several possi-
ble mechanisms. Firstly, the soluble form of fibrinogen
could serve as the bridging molecule between tumor cells
and host cells. Fibrinogen is a dimeric molecule with mul-
tiple integrin or non-integrin binding motifs, and malig-
nant cells often express high levels of fibrinogen receptors,
such as α5β1,  αvβ3 integrins or ICAM-1 molecule. If
fibrinogen were to bind to ICAM-1 on endothelial cells, it
might promote stable adhesion of tumor cells to the
endothelium of target organs. In addition, tumor cells and
platelets can form large aggregates through the binding of
fibrinogen, because platelet αIIbβ3 integrin receptors
have a high affinity for fibrinogen. These aggregates effec-
tively form microemboli in target organs, which can pro-
tect tumor cells from the innate immune system [26,27].
Overall survival after surgery for 240 patients with T2 gastric cancer (A) and 165 patients with T3/T4 gastric cancer (B)  according to the existence of hyperfibrinogenemia Figure 2
Overall survival after surgery for 240 patients with T2 gastric cancer (A) and 165 patients with T3/T4 gastric cancer (B) 
according to the existence of hyperfibrinogenemia. The group with hyperfibrinogenemia (>310 mg/dl) showed a significantly 
lower survival rate than another group (≤310 mg/dl) in T2 cancer. There was no statistically significant survival difference in T3/
T4 cancer according to the plasma fibrinogen level.
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A study by Palumbo and colleagues found that the
number of tumor cells located in the lung was markedly
decreased in fibrinogen deficient mice after 4–24 hours of
tumor inoculation, but at no earlier time points. This sug-
gests that fibrinogen is essential for the sustained adher-
ence of tumor cells to the endothelia of target organs [17].
Recent studies have shown that thrombin might also be
an important modulator of cancer metastasis in vivo. Dur-
ing the conversion of prothrombin to thrombin by pro-
thrombinase, the polypeptide prothrombin fragment 1+2
(F1+2) is released. The plasma F1+2 level is therefore a
useful marker of thrombin generation. A number of stud-
ies have shown that F1+2 plasma levels are elevated in
patients with specific types of malignancies [4,28,29] but
not in other types [30-32]. Rahr and coworkers reported
no difference in plasma F1+2 levels between patients with
and without gastric cancer [32]. In the present study, pro-
thrombin time (PT) was examined in each patient and no
significant association with the presence of cancer, metas-
tasis, tumor stage or plasma fibrinogen level was found
(data not shown). Moreover, Kerlin and co-workers
recently demonstrated that elevated fibrinogen levels in
hyperfibrinogenemia transgenic mice with suppressed
thrombin activity do not alter the incidence or extent of
thrombus formation [33]. It therefore seems unlikely that
high fibrinogen levels are associated with systemic
thrombin activation and subsequent enhancement of
fibrin formation in gastric cancer.
Although there is sufficient evidence to suggest that ele-
vated fibrinogen levels might aid the development of met-
astatic lesions, we cannot ignore the possibility that this
elevation is simply the result of the tumor mass spreading.
Fibrinogen, which is one of the major acute phase pro-
teins produced by the liver, is greatly enhanced in
response to infection or other inflammatory disorders.
Indeed, the fibrinogen level of all of the patients with pre-
operative acute inflammatory disorders was high. Inflam-
matory proteins, such as IL-6 or CRP, are reported to be
higher in cancer patients compared to non-cancer
patients. In our previous study, we found that CRP level
did not show an independent association with lymphatic
metastasis although plasma fibrinogen level did [16], sug-
gesting that hyperfibrinogenemia, different from high
serum CRP, may not be a simple by-product of inflamma-
tory response caused by tumor progression but might
have some etiologic relevance for tumor metastasis and
accordingly relationship with clinical outcome in gastric
cancer. In this retrospective study as well as our previous
study, however, we could not show the exact causal rela-
tionship between hyperfibrinogenemia and cancer metas-
tasis.
Conclusion
Metastasis is the unequivocal hallmark of cancer. The
acquisition of metastatic ability leads to clinically incura-
ble disease and resultingly worse clinical outcome for
most cancer cell types. Our data, together with the results
of basic experiments in previous studies, raises the idea
that hyperfibrinogenemia causally imparts the hematoge-
nous and lymphatic metastatic progression in patients
with advanced gastric cancer, and is not simply the result
of tumor progression. It also has a prognostic value in T2
gastric cancer, which might suggest hyperfibrinogenemia
has the potential to be prognostic marker in other cancer
type with less frequent peritoneal metastasis. Routinely
examined plasma fibrinogen level is not only the factor to
assess the perioperative hemorrhagic risk but also a useful
biomarker to predict the possible metastasis and worse
prognosis in T2 gastric cancer.
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